Scarica l'app Stockscreener
44.32
0.14%
0.06
Dopo l'orario di chiusura:
45.00
0.68
+1.53%
Precedente Chiudi:
$44.26
Aprire:
$44.12
Volume 24 ore:
1.45M
Relative Volume:
2.08
Capitalizzazione di mercato:
$2.45B
Reddito:
-
Utile/perdita netta:
$-146.66M
Rapporto P/E:
-16.09
EPS:
-2.7541
Flusso di cassa netto:
$-133.21M
1 W Prestazione:
+3.09%
1M Prestazione:
+21.99%
6M Prestazione:
-6.00%
1 anno Prestazione:
+15.99%
Intervallo 1D:
$43.48
$46.67
Intervallo di 1 settimana:
$42.40
$46.67
Portata 52W:
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
Nome
Apogee Therapeutics Inc
Settore
Industria
Telefono
650-394-5230
Indirizzo
221 CRESCENT ST., WALTHAM
Confronta APGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
44.32 | 2.45B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-11-25 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-10 | Iniziato | BofA Securities | Buy |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | Guggenheim | Buy |
| 2023-08-08 | Iniziato | Jefferies | Buy |
| 2023-08-08 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
| 2023-08-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Apogee Therapeutics Inc Borsa (APGE) Ultime notizie
Rhumbline Advisers Has $2.03 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Contrasting argenx (NASDAQ:ARGX) and Apogee Therapeutics (NASDAQ:APGE) - Defense World
APGE Stock Update: Apogee Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Apogee Therapeutics stock maintains buy rating ahead of key trial data - Investing.com Canada
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by California State Teachers Retirement System - Defense World
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? - sharewise
Insider Sell: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Ameriprise Financial Inc. Makes New $259,000 Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewswire
4,824 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by BNP Paribas Financial Markets - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Bank of America Corp DE - Defense World
Millennium Management LLC Has $5.90 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
(APGE) Investment Analysis and Advice - news.stocktradersdaily.com
Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock By Investing.com - Investing.com India
Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock - Investing.com
D. E. Shaw & Co. Inc. Has $445,000 Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Boosts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $94.60 - Defense World
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet - MSN
Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire
How To Trade (APGE) - news.stocktradersdaily.com
Northern Trust Corp Grows Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Q1 Earnings Forecast for APGE Issued By Wedbush - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for APGE - Defense World
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma - marketscreener.com
Apogee Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class (APGE) - Seeking Alpha
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire
BTIG maintains Apogee Therapeutics stock Buy rating, $100 target By Investing.com - Investing.com India
BTIG maintains Apogee Therapeutics stock Buy rating, $100 target - Investing.com
Why Is Apogee Therapeutics Stock Trading Higher On Monday? - Benzinga
Apogee Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Apogee Therapeutics reports positive results from asthma treatment trial - Seeking Alpha
Apogee Therapeutics (APGE) Reports Promising Phase 1b Trial Resu - GuruFocus
Apogee (APGE) Sets Sights on Transformative Achievements in 2025 - GuruFocus
Apogee Therapeutics Q1 Loss Widens - marketscreener.com
Apogee Therapeutics Reports Positive Phase 1b Trial Results - TipRanks
Apogee Therapeutics, Inc. SEC 10-Q Report - TradingView
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $55.3M, vs. FactSet Est of $72.3M Loss - marketscreener.com
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma - The Manila Times
Apogee Therapeutics Reports Positive Phase 1b Trial Results for APG808 in Asthma, Highlighting Durable FeNO Suppression and Potential for Extended Dosing Intervals - Nasdaq
Apogee Therapeutics (APGE) Projected to Post Quarterly Earnings on Monday - Defense World
Apogee Therapeutics chief medical officer sells shares totaling $97,418 By Investing.com - Investing.com Nigeria
Apogee Therapeutics chief medical officer sells shares totaling $97,418 - Investing.com Australia
Apogee Therapeutics Inc Azioni (APGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apogee Therapeutics Inc Azioni (APGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
May 07 '25 |
Sale |
35.75 |
2,725 |
97,419 |
244,448 |
| Dambkowski Carl | Chief Medical Officer |
Apr 02 '25 |
Sale |
36.22 |
3,860 |
139,801 |
247,173 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):